<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00774358</url>
  </required_header>
  <id_info>
    <org_study_id>2007-6-5354</org_study_id>
    <secondary_id>1R01FD004091-01A1</secondary_id>
    <nct_id>NCT00774358</nct_id>
  </id_info>
  <brief_title>Interleukin-2 Treatment for Wiskott-Aldrich Syndrome</brief_title>
  <acronym>WAS</acronym>
  <official_title>Reinstituting Natural Killer Cell Cytotoxicity and Cytoskeletal Dynamics in Wiskott-Aldrich Syndrome With IL-2 Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Soma Jyonouchi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Texas Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Hospital of Philadelphia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Funding Source--FDA OOPD.

      Orphan Product Grant Number--1R01FD004091-01A1

      Context: Wiskott-Aldrich syndrome (WAS) is a fatal, devastating disease with ill-defined
      treatment modalities, which affects young boys. Classic WAS is characterized by a clinical
      triad of thrombocytopenia, eczema and severe, recurrent infections. Despite diagnostic and
      therapeutic advances most WAS patients die at less than 12 years of age due to infections,
      hemorrhage, malignancy or complications from treatments. WAS patients suffer from herpesvirus
      infections as a result of poor Natural Killer (NK) cell function (cytotoxicity). In the
      laboratory, the investigators have seen correction of WAS Natural Killer Cell (NK) function
      after treatment with Interleukin-2 (IL-2).

      Objectives: Initiate a prospective clinical trial by treating WAS subjects with IL-2 and
      using safety as the primary endpoint. Restoration of NK cell cytotoxicity and effects on
      cytoskeletal dynamics are secondary endpoints. The investigators will also observe patient
      clinical status (eczema, infections, use of treatment dose antibiotics, food allergies, etc).

      Study Design/Setting/Participants: This is a prospective clinical trial treating 9 WAS
      subjects in the Clinical Translational Research Center (CTRC) with IL-2.

      Intervention: The investigators propose to subcutaneously administer 0.5 Million Units
      (MU)/m2 of IL-2 daily to WAS subjects for 5 days. Research treatment will be repeated 2 and 4
      months later. Inter-patient dose escalation will be employed to 1 MU/m2 and/or 2 MU/m2 based
      on safety as the primary endpoint.

      Study Measures: The investigators will observe safety and tolerability measures and perform
      assays on subject blood samples prior to and after research treatment to observe improvement
      in NK cell function.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Wiskott-Aldrich syndrome (WAS) is a fatal genetic disease of the immune system that
      results from a mutation of the WAS protein (WASp) gene. Immune cells that carry this mutation
      have a decreased ability to reorganize filamentous actin (F-actin) after activation. As a
      result there are a number of defective immunologic functions, some of which result in
      deficient host defense. The investigators have identified a pervasive deficit in natural
      killer (NK) cell cytotoxicity in WAS patients. WAS patients suffer from conditions that are
      hallmarks of NK cell deficiencies. These include severe herpesvirus infections and B cell
      malignancies. Our lab and others have also found that exposure of WAS subject NK cells to
      IL-2 in vitro restores NK cell function and allows for normal F-actin reorganization. Thus,
      the investigators propose a proof of principal clinical trial to treat WAS subjects with IL-2
      to determine safety and efficacy of IL-2 in this population and if NK cell function is
      restored ex vivo. If IL-2 can circumvent a defective WASp to restore NK cell function, the
      investigators will propose a larger NIH funded efficacy trial of IL-2 in WAS. The
      investigators will also use the in vivo treatment of WAS subjects to forward our mechanistic
      studies of how IL-2 may facilitate F-actin reorganization in the absence of WASp function.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate effects on cytoskeletal dynamics</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Requirement for treatment dose antibiotics</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and severity of infections</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Eczema</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Food allergies</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NK cell cytotoxicity</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Wiskott-Aldrich Syndrome (WAS)</condition>
  <condition>X-linked Thrombocytopenia</condition>
  <arm_group>
    <arm_group_label>Interleukin-2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>We propose to subcutaneously administer 0.5 MU/m2 of IL-2 daily to WAS subjects for 5 days. Research treatment will be repeated 2 and 4 months later. Inter-patient dose escalation will be employed to 1 MU/m2 and/or 2 MU/m2 based on safety as the primary endpoint.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interleukin-2</intervention_name>
    <description>We propose to subcutaneously administer 0.5 MU/m2 of IL-2 daily to WAS subjects for 5 days. Research treatment will be repeated 2 and 4 months later. Inter-patient dose escalation will be employed to 1 MU/m2 and/or 2 MU/m2 based on safety as the primary endpoint.</description>
    <arm_group_label>Interleukin-2</arm_group_label>
    <other_name>IL-2</other_name>
    <other_name>Aldesleukin</other_name>
    <other_name>Proleukin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: Subjects age greater than 24 months

          -  Weight: Subjects greater than 12.5 kilograms

          -  Disease status: WAS classified as Grade 1-4

          -  Informed Consent: Written informed consent of the subject (if an adult) or parental
             permission, and assent of the child subject provided justification is made for the
             inclusion of children in the study

        Exclusion Criteria:

          -  Prior or planned hematopoetic transplant

          -  WAS classified as currently Grade 5 (Malignancy or autoimmune disease including the
             following: Crohn's disease, scleroderma, thyroiditis, inflammatory arthritis, diabetes
             mellitus, oculo-bulbar myasthenia gravis, crescentic IgA glomerulonephritis,
             cholecystitis, cerebral vasculitis, Stevens-Johnson syndrome and bullous pemphigoid .
             Not included here are: Hepatitis C virus induced vasculitis, alopecia areata and
             systemic lupus erythematosus.)

          -  Known previous reaction to IL-2

          -  Subjects taking immunosuppressive medications that might alter study results

          -  Subjects taking nephrotoxic, cytotoxic, cardiotoxic, or hepatotoxic medications
             (including medications for hypertension)

          -  Subjects currently taking systemic corticosteroids (not included here: topical and
             inhaled corticosteroids)

          -  Subjects taking Interferon alpha

          -  Use of any other investigational agent in the last 30 days

          -  Women of childbearing potential not using contraception method(s), as well as women
             who are breastfeeding

          -  Subjects with abnormal cardiac, hepatic and CNS function
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>24 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Soma Jyonouchi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital of Philadelphia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Azuma H, Sakata H, Saijyou M, Okuno A. Effect of interleukin 2 on intractable herpes virus infection and chronic eczematoid dermatitis in a patient with Wiskott-Aldrich syndrome. Eur J Pediatr. 1993 Dec;152(12):998-1000.</citation>
    <PMID>8131820</PMID>
  </reference>
  <reference>
    <citation>Pahwa R, Chatila T, Pahwa S, Paradise C, Day NK, Geha R, Schwartz SA, Slade H, Oyaizu N, Good RA. Recombinant interleukin 2 therapy in severe combined immunodeficiency disease. Proc Natl Acad Sci U S A. 1989 Jul;86(13):5069-73.</citation>
    <PMID>2787027</PMID>
  </reference>
  <reference>
    <citation>Piscitelli SC, Wells MJ, Metcalf JA, Baseler M, Stevens R, Davey RT Jr. Pharmacokinetics and pharmacodynamics of subcutaneous interleukin-2 in HIV-infected patients. Pharmacotherapy. 1996 Sep-Oct;16(5):754-9.</citation>
    <PMID>8888071</PMID>
  </reference>
  <reference>
    <citation>Witzke O, Winterhagen T, Reinhardt W, Heemann U, Grosse-Wilde H, Kreuzfelder E, Roggendorf M, Philipp T. Comparison between subcutaneous and intravenous interleukin-2 treatment in HIV disease. J Intern Med. 1998 Sep;244(3):235-40.</citation>
    <PMID>9747746</PMID>
  </reference>
  <reference>
    <citation>Toren A, Nagler A, Rozenfeld-Granot G, Levanon M, Davidson J, Bielorai B, Kaplinsky C, Meitar D, Mandel M, Ackerstein A, Ballin A, Attias D, Biniaminov M, Rosenthal E, Brok-Simoni F, Rechavi G, Kaufmann Y. Amplification of immunological functions by subcutaneous injection of intermediate-high dose interleukin-2 for 2 years after autologous stem cell transplantation in children with stage IV neuroblastoma. Transplantation. 2000 Oct 15;70(7):1100-4.</citation>
    <PMID>11045650</PMID>
  </reference>
  <reference>
    <citation>Sundin DJ, Wolin MJ. Toxicity management in patients receiving low-dose aldesleukin therapy. Ann Pharmacother. 1998 Dec;32(12):1344-52. Review.</citation>
    <PMID>9876817</PMID>
  </reference>
  <reference>
    <citation>Starr SE, McFarland EJ, Muresan P, Fenton T, Pitt J, Douglas SD, Deveikis A, Levin MJ, Rathore MH; PACTG 299 Study Team. Phase I/II trial of intravenous recombinant interleukin-2 in HIV-infected children. AIDS. 2003 Oct 17;17(15):2181-9.</citation>
    <PMID>14523275</PMID>
  </reference>
  <reference>
    <citation>Gismondi A, Cifaldi L, Mazza C, Giliani S, Parolini S, Morrone S, Jacobelli J, Bandiera E, Notarangelo L, Santoni A. Impaired natural and CD16-mediated NK cell cytotoxicity in patients with WAS and XLT: ability of IL-2 to correct NK cell functional defect. Blood. 2004 Jul 15;104(2):436-43. Epub 2004 Mar 4.</citation>
    <PMID>15001467</PMID>
  </reference>
  <reference>
    <citation>Orange JS, Brodeur SR, Jain A, Bonilla FA, Schneider LC, Kretschmer R, Nurko S, Rasmussen WL, KÃ¶hler JR, Gellis SE, Ferguson BM, Strominger JL, Zonana J, Ramesh N, Ballas ZK, Geha RS. Deficient natural killer cell cytotoxicity in patients with IKK-gamma/NEMO mutations. J Clin Invest. 2002 Jun;109(11):1501-9.</citation>
    <PMID>12045264</PMID>
  </reference>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 16, 2008</study_first_submitted>
  <study_first_submitted_qc>October 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2008</study_first_posted>
  <last_update_submitted>August 14, 2017</last_update_submitted>
  <last_update_submitted_qc>August 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Children's Hospital of Philadelphia</investigator_affiliation>
    <investigator_full_name>Soma Jyonouchi</investigator_full_name>
    <investigator_title>Soma Jyonouchi,MD</investigator_title>
  </responsible_party>
  <keyword>Primary Immunodeficiency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Thrombocytopenia</mesh_term>
    <mesh_term>Wiskott-Aldrich Syndrome</mesh_term>
    <mesh_term>Genetic Diseases, X-Linked</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interleukin-2</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

